164 related articles for article (PubMed ID: 37570809)
1. Comparative Molecular Characterization and Pharmacokinetics of IgG1-Fc and Engineered Fc Human Antibody Variants to Insulin-like Growth Factor 2 Receptor (IGF2R).
Prabaharan CB; Giri S; Allen KJH; Bato KEM; Mercado TR; Malo ME; Carvalho JLC; Dadachova E; Uppalapati M
Molecules; 2023 Aug; 28(15):. PubMed ID: 37570809
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy Targeting IGF2R on Canine-Patient-Derived Osteosarcoma Tumors in Mice and Radiation Dosimetry in Canine and Pediatric Models.
Broqueza J; Prabaharan CB; Allen KJH; Jiao R; Fisher DR; Dickinson R; MacDonald-Dickinson V; Uppalapati M; Dadachova E
Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056067
[TBL] [Abstract][Full Text] [Related]
3. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
[TBL] [Abstract][Full Text] [Related]
4. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
5. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.
Proetzel G; Roopenian DC
Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339
[TBL] [Abstract][Full Text] [Related]
6. Detection and targeting insulin growth factor receptor type 2 (IGF2R) in osteosarcoma PDX in mouse models and in canine osteosarcoma tumors.
Karkare S; Allen KJH; Jiao R; Malo ME; Dawicki W; Helal M; Godson DL; Dickinson R; MacDonald-Dickinson V; Yang R; Hoang B; Gorlick R; Geller DS; Dadachova E
Sci Rep; 2019 Aug; 9(1):11476. PubMed ID: 31391495
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R).
Geller DS; Morris J; Revskaya E; Kahn M; Zhang W; Piperdi S; Park A; Koirala P; Guzik H; Hall C; Hoang B; Yang R; Roth M; Gill J; Gorlick R; Dadachova E
Nucl Med Biol; 2016 Dec; 43(12):812-817. PubMed ID: 27744117
[TBL] [Abstract][Full Text] [Related]
8. Novel Human Antibodies to Insulin Growth Factor 2 Receptor (IGF2R) for Radioimmunoimaging and Therapy of Canine and Human Osteosarcoma.
Broqueza J; Prabaharan CB; Andrahennadi S; Allen KJH; Dickinson R; MacDonald-Dickinson V; Dadachova E; Uppalapati M
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34064450
[TBL] [Abstract][Full Text] [Related]
9. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
[TBL] [Abstract][Full Text] [Related]
10. Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody.
Maeda A; Iwayanagi Y; Haraya K; Tachibana T; Nakamura G; Nambu T; Esaki K; Hattori K; Igawa T
MAbs; 2017 Jul; 9(5):844-853. PubMed ID: 28387635
[TBL] [Abstract][Full Text] [Related]
11. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
12. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
[TBL] [Abstract][Full Text] [Related]
13. Characterization of IGF2R Molecular Expression in Canine Osteosarcoma as Part of a Novel Comparative Oncology Approach.
Boisclair C; Dickinson R; Giri S; Dadachova E; MacDonald-Dickinson V
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768202
[TBL] [Abstract][Full Text] [Related]
14. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.
Mackness BC; Jaworski JA; Boudanova E; Park A; Valente D; Mauriac C; Pasquier O; Schmidt T; Kabiri M; Kandira A; Radošević K; Qiu H
MAbs; 2019 Oct; 11(7):1276-1288. PubMed ID: 31216930
[TBL] [Abstract][Full Text] [Related]
15. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
[TBL] [Abstract][Full Text] [Related]
16. Initial insights into the interaction of antibodies radiolabeled with Lutetium-177 and Actinium-225 with tumor microenvironment in experimental human and canine osteosarcoma.
Giri S; Allen KJH; Prabaharan CB; Ramirez JB; Fiore L; Uppalapati M; Dadachova E
Nucl Med Biol; 2024 May; 134-135():108917. PubMed ID: 38718557
[TBL] [Abstract][Full Text] [Related]
17. Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases.
Ying T; Feng Y; Wang Y; Chen W; Dimitrov DS
MAbs; 2014; 6(5):1201-10. PubMed ID: 25517305
[TBL] [Abstract][Full Text] [Related]
18. An engineered human IgG1 antibody with longer serum half-life.
Hinton PR; Xiong JM; Johlfs MG; Tang MT; Keller S; Tsurushita N
J Immunol; 2006 Jan; 176(1):346-56. PubMed ID: 16365427
[TBL] [Abstract][Full Text] [Related]
19. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn
Mester S; Evers M; Meyer S; Nilsen J; Greiff V; Sandlie I; Leusen J; Andersen JT
MAbs; 2021; 13(1):1893888. PubMed ID: 33691596
[TBL] [Abstract][Full Text] [Related]
20. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
